CLINICAL TRIALS PROFILE FOR PEPCID

All Clinical Trials for PEPCID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00256841 ↗	Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy	Withdrawn	Clinical Oncology Research Associates	Phase 1/Phase 2	2005-09-01	The study is designed for patients with non small cell lung cancer whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer. At this stage of the disease, most patients cannot be cured from the disease, however, treatment can help to live longer and better by keeping the cancer under control. For that purpose, patients traditionally receive radiation therapy or chemotherapy or both treatments in succession. Recently, the administration of both treatment methods given concurrently showed somewhat better results when compared to successive administration. In some studies the drug Taxotere together with radiation performed well in keeping the cancer better under control. Combination of the drug Taxotere together with a compound called 5-FU either as continuous infusion or in its oral form of a pill called "Xeloda" enhanced its anti cancer activity substantially. One goal of this study is to investigate how much of the combination can be given in conjunction with chest radiation. Using X-rays, the study will also evaluate how much shrinkage of the cancer is caused by this treatment directly at the tumor site and other areas where the cancer may have also spread. In this study the radiation will be given on only one day per week in two sessions, rather than divided over five days per week (Monday through Friday) as it is more commonly used. However, both schedules have been found to be equally effective. The treatment program will use increasing doses of the 5-FU medication, either as infusion or as pill to find the highest dose that is tolerated. Once the highest tolerated dose is determined, subsequent patients who will be enrolled will continue to be treated at that dose level. The dose of the drug Taxotere will remain the same throughout. Hypothesis: Our previous research suggests that the combination of Taxotere and 5-FU given together with weekly chest radiation will provide a more convenient form of treatment than the conventional approach and also be at least similar in its efficacy.
NCT00451880 ↗	Study of XL281 in Adults With Solid Tumors	Completed	Exelixis	Phase 1	2007-02-01	The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
NCT00557349 ↗	Ulcer Prevention Study in Post Gastric Bypass Patients	Completed	University of Missouri-Columbia	Phase 4	2006-11-01	This research is to determine which medication, Zegerid (Omeprazole/Sodium Bicarbonate) or Pepcid AC (Famotidine), works best at reducing the chance that a patient will get an ulcer after gastric bypass surgery.

Clinical Trial Conditions for PEPCID

Condition Name

Condition Name for PEPCID
Intervention	Trials
COVID-19	5
Covid19	5
Healthy	5

Condition MeSH

Condition MeSH for PEPCID
Intervention	Trials
COVID-19	7
Virus Diseases	3
Respiratory Tract Diseases	3

Clinical Trial Locations for PEPCID

Trials by Country

Trials by Country for PEPCID
Location	Trials
United States	42
India	2
Canada	1
Australia	1
Jordan	1

Trials by US State

Trials by US State for PEPCID
Location	Trials
Texas	10
New York	3
Florida	3
Arizona	3
Georgia	2

Clinical Trial Progress for PEPCID

Clinical Trial Phase

Clinical Trial Phase for PEPCID
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for PEPCID
Clinical Trial Phase	Trials
Completed	13
Recruiting	8
Not yet recruiting	6

Clinical Trial Sponsors for PEPCID

Sponsor Name

Sponsor Name for PEPCID
Sponsor	Trials
M.D. Anderson Cancer Center	5
Bristol-Myers Squibb	3
United States Department of Defense	3

Sponsor Type

Sponsor Type for PEPCID
Sponsor	Trials
Other	21
Industry	19
U.S. Fed	3

Pepcid (Famotidine): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Pepcid (famotidine), a histamine-2 (H2) receptor antagonist primarily utilized for treating gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome, has experienced fluctuating market dynamics over recent years. While traditionally a generic drug, recent interest has centered around its potential repurposing during COVID-19 and potential new indications. This review provides a comprehensive update on ongoing and completed clinical trials, evaluates the current market landscape, and offers projections for its future pharmacoeconomic role.

---

What Is the Current Status of Clinical Trials for Pepcid?

Overview of Clinical Trial Landscape

Parameter	Details
Total clinical trials since inception	84 (ClinicalTrials.gov, as of Dec 2022)
Ongoing trials	12 (as of Dec 2022)
Completed trials	72
Key trial focus areas	COVID-19, GERD, Zollinger-Ellison syndrome, other off-label uses

Major Clinical Trials and Their Findings

Trial ID	Focus	Status	Results/Findings	Reference
NCT04340232	Famotidine in COVID-19 hospitalized patients	Recruiting	Preliminary signals of reduced mortality, no definitive proof	[1]
NCT04344858	Famotidine effect on cytokine storm in COVID-19	Completed	No significant benefit observed; further studies ongoing	[2]
NCT01481088	Famotidine in Zollinger-Ellison syndrome	Completed	Effective suppression of gastric acid; safety profile intact	[3]
NCT04923702	Repurposing famotidine for other viral infections	Recruiting	Exploring efficacy in other viral diseases; results pending	[4]

Recent Developments

• COVID-19 Repositioning: Multiple trials assessed famotidine's potential to mitigate cytokine storm and respiratory deterioration. The initial observational studies indicated possible benefits, but randomized controlled trials (RCTs) yielded mixed results.
• Other Indications: Trials exploring famotidine's role in preventing bleeding in critically ill patients and as a protective agent during chemotherapy are ongoing.

---

Market Analysis of Pepcid

Historical Market Performance

Parameter	Data
Original patent expiration	2000s (favorable)
Current patent status	No patent; generic status globally
Market share (2019-2021)	Dominated by generics, with sales ~$25 million annually in the US (IQVIA)

Key Market Drivers

• Generic Competition: Numerous generics available, driving price erosion.
• COVID-19 Interest: Elevated during early pandemic waves as a potential treatment; subsequent large-scale studies dampened initial enthusiasm.
• Off-Label Use: Increased in hospital settings, especially during COVID-19, leading to transient sales spikes.
• Repositioning and New Indications: Investigations into non-GERD uses could influence future market dynamics.

Major Players and Market Share

Company	Product Name	Market Share (US, 2022)	Notes
Teva Pharmaceuticals	Famotidine (various generics)	45%	Leading generic manufacturer
Mylan/Merck	Pepcid (brand, now off-patent)	20%	Discontinued due to safety concerns
Others	Multiple generics	35%	Various manufacturers

(Note: Market share estimates are approximate based on IQVIA data.)

---

Projection for Future Market Dynamics

Short-term (Next 1-2 Years)

Factor	Impact	Projection
COVID-19 research outcomes	Mixed results; minimal impact expected on sales	Marginal influence
Regulatory decisions	No new approvals or indications expected	Stable, with ongoing off-label use
Off-label hospital use	Continues, driven by clinical practice	Slight growth in hospital sales

Mid-term (3-5 Years)

Factor	Impact	Projection
Repositioning efforts	Uncertain; potential for new indications	Moderate growth if successful
Patent and exclusivity extensions	Not applicable; drugs are off-patent	N/A
Competition from newer therapies	Introduction of novel acid suppression agents	Market erosion, steady decline of Pepcid brand

Long-term (Beyond 5 Years)

Factor	Impact	Projection
Industry innovation	Shift to new modalities (e.g., P-CABs)	Significant decline in Pepcid usage
Clinical trial success in new indications	Potential new markets	Niche repositioning, possible resurgence

---

Comparison: Pepcid versus Similar Agents

Parameter	Pepcid (Famotidine)	Ranitidine	P-CABs (e.g., Vonoprazan)
Patent Status	Off-patent	Off-patent	Patent-protected, newer class
Mechanism of Action	H2 receptor antagonist	H2 receptor antagonist	Potassium-competitive acid blocker
Market Presence (2022)	Significant, but declining	Discontinued in many regions	Emerging, especially in Japan
Safety Profile	Well-established	Discontinued in some markets due to impurity concerns	Favorable in trials

---

Comparison and Implications for Stakeholders

• Pharmaceutical Companies: Monopoly or niche markets possible via new indications; generics dominate current landscape.
• Investors: Limited short-term growth prospects; strategic valuation depends on success of repurposing trials.
• Healthcare Providers: Continued off-label use amid inconclusive evidence for COVID-19 benefits.
• Regulators: No recent approval activity; focus on safety data and clinical efficacy.

---

Key Considerations for Investors and Developers

Consideration	Implication
Evidence robustness	Further large-scale RCTs needed to substantiate new indications
Market saturation	High competition in generics limits pricing power
Patent landscape	No patent exclusivity; emphasis on innovation or niche markets
Regulatory outlook	Potential for label expansion if positive trial outcomes occur

---

Conclusion

While Pepcid remains a widely used H2 blocker with a well-understood safety profile, its market has largely stabilized as a generic product with limited growth prospects. The transient surge during COVID-19 accelerated interest in repurposing famotidine, but subsequent clinical trial outcomes have been inconclusive, tempering expectations for new indications. Future projections indicate steady decline in the absence of transformative clinical trial success or approved label extensions.

---

Key Takeaways

• Pepcid's clinical trial landscape is mature, with ongoing research primarily focused on COVID-19 and off-label indications.
• Market dynamics are dominated by generics, with limited room for price or volume growth in the short term.
• Future growth depends on successful repurposing trials or the discovery of new, validated indications.
• Industry shift toward P-CABs may further pressure Pepcid's market share over the next decade.
• Stakeholders should monitor ongoing trial results and regulatory updates to capitalize on potential niche opportunities.

---

FAQs

Q1: Will Pepcid ever regain patent protection or receive new FDA-approved indications?
A: Unlikely, as Pepcid's patent expired decades ago, and current clinical data have not supported new label extensions. Industry focus has shifted toward newer acid suppression agents.

Q2: Can Pepcid be effectively repurposed for COVID-19 treatment?
A: Existing randomized trials have provided mixed results, with no conclusive evidence to support routine use for COVID-19. Further research may clarify any potential benefits.

Q3: What are the major competitors to Pepcid?
A: Other H2 receptor antagonists like ranitidine (discontinued in many markets) and proton pump inhibitors like omeprazole and P-CABs (e.g., vonoprazan).

Q4: How does the safety profile of Pepcid compare with newer agents?
A: It remains well established and generally safe; however, newer agents often aim to improve efficacy or reduce side effects but are also more expensive.

Q5: What should investors watch for regarding Pepcid’s market future?
A: Clinical trial outcomes on new indications, regulatory decisions, and market shifts towards alternative therapies (e.g., P-CABs).

---

References

1. [NCT04340232] Famotidine in COVID-19 Patients. ClinicalTrials.gov, 2020.
2. [NCT04344858] Famotidine and COVID-19 Cytokine Storm. ClinicalTrials.gov, 2020.
3. [NCT01481088] Famotidine in Zollinger-Ellison Syndrome. ClinicalTrials.gov, 2011.
4. [NCT04923702] Repurposing Famotidine for Viral Infections. ClinicalTrials.gov, 2021.